Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hydroxychloroquine + clindamycin
- Development stage
- Phase 3
- Lead developer
- Sanofi
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination of hydroxychloroquine, an antimalarial and immunomodulatory agent, with clindamycin, an antibiotic effective against anaerobic bacteria and various gram-positive organisms. This combination has shown enhanced efficacy in treating malaria by improving parasite clearance and therapeutic response compared to monotherapy. The combination requires careful monitoring due to potential cardiovascular risks and drug interactions.
02
Targets
ACE2 (Angiotensin-converting enzyme 2)Bacterial 50S ribosomal subunitFe2+-heme in digestive vacuole
Beyond the preview
Go deeper on hydroxychloroquine + clindamycin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hydroxychloroquine + clindamycin.